title: Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin.
abstract: In a prospective, multicentre double-blind trial, 151 patients over the age of 65 years were randomly assigned to receive either cefepime 2 g every 12 h for a minimum of 3 days and up to 14 days or ceftriaxone 1 g every 12 h for a minimum of 3 days and up to 14 days. Antibiotics were maintained until 48 h after fever had resolved; no other antibiotics were permitted. The average age in each group exceeded 77 years and significant co-morbidity was found in the majority of patients. The mean total duration of therapy was 5.8+/-2.4 days for the cefepime group and 6.7+/-2.7 days for the ceftriaxone group (P = 0.06). The clinical success rate at the end of therapy was 79.1% with cefepime and 75.4% with ceftriaxone (P = 0.62). At the end of follow-up, 91.7% of the cefepime-treated patients and 86.5% of the ceftriaxone patients had a satisfactory clinical response (P = 0.38). In 35 bacteriological evaluable patients, potential pathogens were eradicated in all but one patient receiving cefepime. Seven patients in each group died during the study period but in each case the death was unrelated to study drug. The commonest side-effect was diarrhoea (cefepime, five patients; ceftriaxone, two patients). The clinical and microbiological efficacy of cefepime is similar to that of ceftriaxone in elderly patients with community-acquired pneumonia requiring hospitalization. Cefepime is an appropriate choice for the treatment of community-acquired respiratory tract infections in the elderly.
authors.affiliation: Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: R F
authors.initials: RF
authors.lastname: Grossman
authors.forename: D A
authors.initials: DA
authors.lastname: Campbell
authors.forename: S J
authors.initials: SJ
authors.lastname: Landis
authors.forename: G E
authors.initials: GE
authors.lastname: Garber
authors.forename: G
authors.initials: G
authors.lastname: Murray
authors.forename: H G
authors.initials: HG
authors.lastname: Stiver
authors.forename: R
authors.initials: R
authors.lastname: Saginur
authors.forename: R A
authors.initials: RA
authors.lastname: McIvor
authors.forename: J
authors.initials: J
authors.lastname: Laforge
authors.forename: C
authors.initials: C
authors.lastname: Rotstein
authors.forename: J
authors.initials: J
authors.lastname: Dubois
authors.forename: M
authors.initials: M
authors.lastname: Rivard
authors.forename: F
authors.initials: F
authors.lastname: Boulerice
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077723:Cefepime; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D002511:Cephalosporins; D002443:Ceftriaxone; D000077723:Cefepime